San Francisco launches first human trial of semaglutide for methamphetamine addiction. No FDA-approved meds exist for stimulant use disorders. Here's what the science says.
Obesity and addiction share dopamine dysfunction, reward circuit dysregulation, and cross-sensitization. GLP-1 drugs treat both because they target the shared biology of compulsive…
Tirzepatide (Mounjaro) cut alcohol intake over 50% in rodents via dual GLP-1/GIP mechanism. How does it compare to semaglutide for addiction? The preclinical evidence.
From the first rodent amphetamine studies to the 606,434-patient BMJ mega-study. A chronological reference of every major GLP-1 addiction study. Bookmark this.
The Lancet AUD trial showed improved liver biomarkers alongside reduced drinking. GLP-1s also have independent MASLD/MASH data. For people with alcohol-related liver damage, this dual…
A GLP-1 receptor gene variant (rs6923761) alters alcohol reward and brain imaging responses. Pharmacogenomics may predict who benefits from GLP-1 addiction treatment.
Not approved for addiction yet. Won't replace therapy. Evidence strongest for alcohol. Could work alongside existing meds. Access and cost matter. What the experts want you to know.
FDA found no increased suicide or self-harm risk in 2.24 million GLP-1 users. Requests removal of warning labels. NIH study found lower suicidal ideation risk. What this means for addiction…
GLP-1 users described quieting of food noise. Dr. Al-Aly extended it to drug noise. The reframing reflects real neuroscience — and it matters for destigmatizing addiction.
The first major randomized controlled trial of semaglutide for alcohol use disorder shows significant reductions in heavy drinking days, cravings, and liver biomarkers. Full breakdown of…
People on semaglutide keep saying the same thing: alcohol, cigarettes, and cravings just stopped mattering. It's not willpower. It's not aversion. The science calls it reduced incentive…
Multiple studies show semaglutide is associated with dramatically lower opioid overdose rates. With 100,000+ annual overdose deaths in the US, here's what the evidence says about GLP-1…
Semaglutide users show 32% lower risk of tobacco use disorder. Active NIH trials are testing GLP-1 drugs for smoking cessation. Here's the clinical evidence and the brain science behind it.
Only 3 medications are FDA-approved for alcohol use disorder. How does semaglutide's reward pathway mechanism compare to naltrexone, disulfiram, and acamprosate? A practical breakdown for…
GLP-1 receptors in the brain's VTA, nucleus accumbens, and prefrontal cortex modulate dopamine, GABA, and glutamate signaling. Here's how semaglutide and tirzepatide may reduce addiction…
There are zero FDA-approved medications for cannabis use disorder. A study in Molecular Psychiatry shows semaglutide associated with 44% reduction in CUD. Here's why this matters.
Social media reports of GLP-1 users losing interest in gambling and compulsive shopping. The dopamine science supports the possibility — but clinical evidence is thin. Here's what we know…
When people stop GLP-1 medications, appetite returns. Does drug craving rebound the same way? The biggest open question in GLP-1 addiction research, explained.
A living tracker of actively recruiting clinical trials testing semaglutide and other GLP-1 drugs for alcohol, nicotine, opioid, and other addictions. Eligibility, locations, and how to…
Washington University's landmark 2026 BMJ study of 606,434 veterans finds GLP-1 medications reduce risk of substance use disorders across alcohol, cannabis, cocaine, nicotine, and opioids…
What neuroscience says about GLP-1 medications and food noise. Reward circuitry, food addiction research, and how semaglutide changes the brain's relationship with food.
Can GLP-1 medications help you quit smoking? We review the UNC trial subanalysis, preclinical evidence, active clinical trials, and the reward-pathway mechanism.
GLP-1 medications for binge eating disorder: clinical evidence, mechanism, and why medication alone isn't enough. Treatment approach for BED with obesity.
Why GLP-1 medications affect multiple addictions: the dopamine connection. Mesolimbic pathways, cross-addiction evidence, and what clinical trials are testing next.
The largest study yet: 606,000 U.S. veterans on GLP-1 medications showed 14% lower risk of developing any new substance use disorder, plus fewer overdoses, hospitalizations, and deaths.
Can Ozempic help with addiction? Is semaglutide FDA-approved for alcoholism? Will cravings come back if I stop? 15 questions about GLP-1 medications and substance use, answered with sources.
The JAMA Psychiatry studies on GLP-1 and alcohol use disorder explained. Swedish registry data, UNC randomized trial, mechanism, and what it means for treatment.
Preclinical research shows semaglutide markedly reduces cocaine-seeking in animal models. A tirzepatide meth trial is already recruiting. Here's the state of GLP-1 and stimulant addiction…
The first RCT of a GLP-1 medication for opioid use disorder. 20 patients, 3 weeks, 40% craving reduction — and some participants reported zero cravings. What the Grigson trial means.
Inside the Lähteenvuo registry study from JAMA Psychiatry: semaglutide linked to 36% fewer alcohol-related hospitalizations across 228,000 Swedish patients with AUD. The largest study of…
GLP-1 medications quiet 'food noise.' But patients also report silenced cravings for alcohol, nicotine, and other substances. Neuroscience suggests these may all be the same signal.
Reports of reduced gambling urges on GLP-1 medications are piling up. But with zero clinical trials and only anecdotal evidence, here's where the science actually stands.
A practical guide to bringing up GLP-1 research with your doctor, whether you're managing weight, diabetes, or curious about the addiction data. What to say, what to ask, what to expect.
Breakdown of the landmark Wang/Volkow study showing semaglutide associated with 44% reduced risk of cannabis use disorder. Published in Molecular Psychiatry, 2024.
NIDA Director Nora Volkow's landmark study found semaglutide associated with 42-68% lower opioid overdose risk. We break down the data from 33,000 patient records.
A deep breakdown of the 2025 JAMA Psychiatry randomized clinical trial showing semaglutide reduced alcohol cravings, heavy drinking days, and total consumption in adults with alcohol use…
Live tracker of every clinical trial testing GLP-1 medications for smoking and nicotine cessation. UNC Chapel Hill, UT Houston, Oklahoma, Ottawa — status, design, and what the data means so…